BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Therapeutic Court Association of Washington and Washington Association of Drug Courts - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://tcaofwa.org
X-WR-CALDESC:Events for Therapeutic Court Association of Washington and Washington Association of Drug Courts
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T140000
DTEND;TZID=America/Los_Angeles:20260506T150000
DTSTAMP:20260515T105452
CREATED:20260327T005426Z
LAST-MODIFIED:20260327T005426Z
UID:9266-1778076000-1778079600@tcaofwa.org
SUMMARY:Update on the Diversification of Kratom-Derived Products: 7-Hydroxymitragynine\, Pseudoindoxyl and Beyond
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 6\, 2026 5:00 – 6:00 PM ET \nThis session will provide a background on traditional kratom and an overview of the recent proliferation of novel\, kratom-derived products. Industry marketing and media coverage will be described as all influence public health responses. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom\, 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks. \n\nORN Spring 2026: Update on the diversification of kratom-derived products: 7-hydroxymitragynine\, pseudoindoxyl\, and beyond \n\n\n\n\n\n\n\n\nDescription:\n\nThis talk will provide a background on traditional kratom and an overview of the recent proliferation of novel\, kratom-derived products. Industry marketing\, confused media coverage\, and dynamic government policy will be described\, as all influence public health responses. What is known about the harm-reduction aspects of these kratom compounds will be considered. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom\, 7-hydroxymitragynine (7-OH)\, and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks. Case reports will be used to highlight the complexity of assessing\, diagnosing\, and treating patients consuming new kratom-derived products. Ample time for attendee Q&A will be reserved to facilitate learning and discussion. \n\nLearning objectives:\nUpon completion\, participants will be able to: \n1. Upon completion\, describe the basic pharmacology\, toxicology\, effects\, risks\, and benefits associated with kratom and kratom-derived products containing 7-hydroxymitragynine (“7-OH”)\, mitragynine pseudoindoxyl (“pseudo”)\, along with related compounds such as kava\, and MGM-15.\n2. Upon completion\, participants will be able to engage in improved identification of kratom product use\, conduct highly specified clinical assessments\, and better diagnosis and manage SUDs related to kratom-derived products in a data-informed and patient-centered manner.\n3. Upon completion\, participants will be able to define the dynamic state and federal policy and regulatory landscape surrounding kratom and kratom-derived products. \n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\n\nSpeaker:\n\nDr. Kirsten Smith \n\nKirsten Smith\, Ph.D.\, L.M.S.W.\, is one of the nation’s leading clinical experts on kratom. Dr. Smith has authored over 90 peer-reviewed publications\, most focused on kratom or related topics\, including kava and tianeptine. Between 2023-2025\, Dr. Smith was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences in the Johns Hopkins University School of Medicine. She joined Johns Hopkins after earning her Masters in Social Work from the University of Kentucky\, Ph.D. from the University of Louisville\, and after completing a 4-year postdoctoral fellowship at the National Institute on Drug Abuse Intramural Research Program (NIDA IRP). At NIDA IRP Dr. Smith completed her K99-funded project that involved a national ecological momentary assessment of kratom use and a controlled drug administration substudy that investigated the acute effects of commercial kratom products. Her NIDA R00-funded study at Johns Hopkins examined the pharmacokinetics/pharmacodynamics of kratom and assessed spontaneous kratom withdrawal among daily consumers. Dr. Smith was awarded a NIDA R01 to investigate the safety\, tolerability\, and human abuse potential of kratom extract in healthy adults\, which is ongoing. She has also conducted numerous surveys and qualitative data projects on kratom and 7-hydroxymitragynine use. Presently\, Dr. Smith is transitioning from academia to clinical practice but consults on kratom regularly and welcomes opportunities for collaboration. \n\n\nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\n\nRegister Here: ORN Spring 2026: Update on the diversification of kratom-derived products: 7-hydroxymitragynine\, pseudoindoxyl\, and beyond\n\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/update-on-the-diversification-of-kratom-derived-products-7-hydroxymitragynine-pseudoindoxyl-and-beyond/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260501T090000
DTEND;TZID=America/Los_Angeles:20260501T100000
DTSTAMP:20260515T105452
CREATED:20260327T004835Z
LAST-MODIFIED:20260327T004835Z
UID:9264-1777626000-1777629600@tcaofwa.org
SUMMARY:Mindfulness-Based Relapse Prevention (MBRP) for People with HIV and a Substance Use Disorder
DESCRIPTION:ORN Partner Organization Sponsor: National Alliance for HIV Education and Workforce Development (NAHEWD) \nFriday May 1\, 2026 12:00 – 1:00 PM ET \nThis lecture will explore the basic tenets of MBRP and the application of this approach with people living with HIV. The session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series is highlighting various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. \nThis session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This lecture will explore the basic tenets of MBRP and the application of this approach with people living with HIV. Learning objectives: 1. Understand the unique intersection – how HIV and substance use interact and affect each other. 2. Understand the theoretical foundations of MBRP. 3. Putting the principles of MBRP into action – learning mindfulness techniques. 4. Implementing culturally responsive care for diverse populations of people living with HIV in recovery. \nRegister Here: Webinar Registration – Zoom \n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/mindfulness-based-relapse-prevention-mbrp-for-people-with-hiv-and-a-substance-use-disorder/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-174430.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T110000
DTEND;TZID=America/Los_Angeles:20260416T123000
DTSTAMP:20260515T105452
CREATED:20260327T001212Z
LAST-MODIFIED:20260327T001212Z
UID:9242-1776337200-1776342600@tcaofwa.org
SUMMARY:New Standards for Adolescent and Transition-Aged Youth in The ASAM Criteria\, Fourth Edition: Volume 2
DESCRIPTION:Forwarded from email sent by AllRise on 3/25/26 \nThe ASAM Criteria\, Fourth Edition\, Volume 2: Adolescents and Transition Aged Youth—the first of its kind in youth addiction and mental health care—is scheduled for release in spring 2026. This groundbreaking resource meets an urgent national need by providing developmentally specific guidance for identifying risk\, determining the appropriate level of care\, and coordinating treatment for young people. \n\n\nLed by experts from The American Society of Addiction Medicine (ASAM) and Hazelden Betty Ford\, this 101‑level session explores how the forthcoming edition addresses the changing landscape of youth and young adult substance use and mental health care—and why these shifts offer renewed hope for improving long‑term outcomes for young people. \n\n\nYou’ll develop a baseline understanding of the core principles guiding the aspirational vision of care for adolescents and transition‑aged youth\, while gaining clarity on key details surrounding the release of the criteria and the supporting training opportunities. \n\nLearning Objectives: \n\n\nUnderstand why adolescents and transition‑aged youth require developmentally distinct assessment and treatment approaches rather than adult‑oriented care. \n\n\nExamine family engagement and how family‑driven\, youth‑guided care transforms outcomes. \n\n\nIdentify best practices for prevention\, early intervention\, and integrating mental health treatment for co‑occurring conditions in young people. \n\n\nExplore how the Fourth Edition promotes a model of care that integrates services across health care\, schools\, community programs\, family systems\, and juvenile justice. \n\n\nCan’t attend on the scheduled date?\nAll of our webinars and hybrid events are recorded. Register and you’ll receive notice when the recording is available to watch at your convenience. \n*A certificate of completion will be offered via download\, for attending this event from the webinar console. Please note\, this event has NOT been approved for continuing education (CE) credit. The participant is responsible to verify if this activity meets their continuing education board requirements in order to gain credit. \nOn-Demand Webinars\nView Now \nQuestions? Contact Us. \n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/new-standards-for-adolescent-and-transition-aged-youth-in-the-asam-criteria-fourth-edition-volume-2/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Support,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2025/10/image-16.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260413T110000
DTEND;TZID=America/Los_Angeles:20260413T120000
DTSTAMP:20260515T105452
CREATED:20260327T005846Z
LAST-MODIFIED:20260327T005846Z
UID:9270-1776078000-1776081600@tcaofwa.org
SUMMARY:Medetomidine Impacts on Clinical Management and Systems of Care
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 13\, 2026 5:00 – 6:00 PM ET \nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nDescription:\n\nMedetomidine\, a highly potent veterinary alpha-2 adrenergic agonist\, has recently emerged as a significant adulterant within the U.S. illicit opioid supply. This presentation entitled will review the introduction of medetomidine in the U.S. drug supply\, the pharmacology and clinical effects of medetomidine\, and the distinguishing features of medetomidine toxicity and withdrawal. We will outline emerging treatment strategies emphasizing early\, aggressive alpha-2 agonist therapy; nuanced antiemetic approaches; when and how to escalate to IV dexmedetomidine; and approaches to concurrent opioid withdrawal management. Participants will gain insight into diagnostic challenges\, observation and disposition considerations\, and strategies for system-level preparedness. \nLearning objectives:\nAt the conclusion of this seminar\, attendees should be able to: \n\nDescribe the emergence of medetomidine as an illicit drug adulterant and its impact on overdose toxicity and withdrawal presentations.\nRecognize the clinical features of medetomidine toxicity and differentiate medetomidine withdrawal from withdrawal syndromes.\nApply evidence-informed strategies for early\, aggressive management of medetomidine withdrawal\, including the use of alpha-2 agonists and antiemetic therapies.\nIdentify system-level challenges posed by medetomidine and outline approaches to multidisciplinary coordination.\n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\nSpeaker: \nMichael Lynch\, MD \n\nDr. Michael Lynch is an associate professor of Emergency Medicine\, Toxicology\, and Addiction Medicine at the University of Pittsburgh where he works clinically in several UPMC hospitals. He is currently Senior Medical Director for Quality and Substance Use Disorder Services at UPMC Health Plan. He previously served as the first Medical Director of the PA Department of Drug and Alcohol Programs and was Medical Director of the Pittsburgh Poison Center for 10 years. Dr. Lynch is the founder and director of the UPMC Medical Toxicology Telemedicine Bridge Clinic. \nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\nRegister Here: ORN Spring 2026: Medetomidine Impacts on Clinical Management and Systems of Care\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/medetomidine-impacts-on-clinical-management-and-systems-of-care/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260403T090000
DTEND;TZID=America/Los_Angeles:20260403T100000
DTSTAMP:20260515T105452
CREATED:20260327T004538Z
LAST-MODIFIED:20260327T004538Z
UID:9260-1775206800-1775210400@tcaofwa.org
SUMMARY:Evidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV
DESCRIPTION:Brought to you by Opioid Research Network \nEvidence-Based Treatment for Stimulant Use Disorders Among Populations at Elevated Risk for HIV \nFriday April 3\, 2026 12:00 – 1:00 PM ET \nORN Partner Organization Sponsor: National Alliance for HIV Education and Workforce Development (NAHEWD) \nThis lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. The session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series is highlighting various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. \nThis session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. This lecture will review safety optimization strategies and evidence-based treatments for stimulant use disorders\, including special attention to populations at elevated risk of HIV. By the end of the presentation\, participants will be able to: 1. Contextualize stimulant use disorder and substance use among populations at elevated risk for HIV using epidemiology and syndemic theory. 2. Apply safety optimization techniques to support the wellness of people who use stimulants. 3. Translate clinical research on treatments for stimulants into therapeutic prescribing practices. \nRegister Here: Webinar Registration – Zoom
URL:https://tcaofwa.org/event/evidence-based-treatment-for-stimulant-use-disorders-among-populations-at-elevated-risk-for-hiv/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-174430.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260315T000000
DTEND;TZID=America/Los_Angeles:20260318T235959
DTSTAMP:20260515T105452
CREATED:20260212T062258Z
LAST-MODIFIED:20260212T062258Z
UID:8706-1773532800-1773878399@tcaofwa.org
SUMMARY:2026 National Conference on Juvenile Justice
DESCRIPTION:Join the National Council of Juvenile and Family Court Judges (NCJFCJ) in Minneapolis for our 2026 National Conference on Juvenile Justice\, March 15-18\, 2026\, at the Hyatt Regency Minneapolis. The conference will feature amazing presentations on current and cutting-edge topics that will inspire you\, broaden your knowledge\, and provoke discussions about issues facing the juvenile and family court system. \nFor 88 years\, the NCJFCJ has led systems to change embracing the values of Compassion\, Leadership\, Education\, and Community through our network of more than 30\,000 juvenile and family court professionals who share in the mission of this organization. \n  \nNCJFCJ Current Member Conference Registration \n\nBy March 6\, 2026 – $745.00\nAfter March 6\, 2026 (late/onsite) – $795.00\n\nNCJFCJ Non-Member \n\nBy March 6\, 2026 – $945.00 \nAfter March 6\, 2026 (late/onsite) – $995.00\n\nPayment/Cancellation Policy:  \nPayment is required upon registration. For conference participants\, requests to cancel conference registration must be made in writing and received by email\, fax\, or postmarked by February 17\, 2026\, and will incur a $100 administrative fee. For questions or to register multiple participants\, please contact  MORGAN BULLOCK NCJFCJ\, at mbullock@ncjfcj.org or (775) 507-4801. No refunds will be issued after February 17\, 2026. \nRegistration and Curriculum Questions \nFor questions regarding registration or to register multiple participants\, please contact MORGAN BULLOCK NCJFCJ\, at mbullock@ncjfcj.org or (775) 507-4801.  \nQuestions regarding a proposal or the curriculum\, please contact Emma Schiller Carpenter\, Conference and Events Manager\, NCJFCJ\, at eschiller@ncjfcj.org or (775) 507-4831. \nSponsorship\, Advertising and Exhibitor Opportunities  \nWe invite you to join the NCJFCJ’s 2026 National Conference on Juvenile Justice in Minneapolis as a sponsor or an exhibitor! Space and opportunities are available on a first-come\, first-served basis. You may register here or for questions and to discuss opportunities\, contact Ardis Parmer at ardis.parmer@gmail.com or (775) 772-9121. \nFor more info: NCJFCJ
URL:https://tcaofwa.org/event/2026-national-conference-on-juvenile-justice/
LOCATION:Hyatt Regency Minneapolis\, 1300 Nicollet Mall\, Minneapolis\, MN\, 55403
CATEGORIES:Advocacy,Child Welfare,Judges,Juvenile Justice,SUD
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260129T100000
DTEND;TZID=America/Los_Angeles:20260129T110000
DTSTAMP:20260515T105452
CREATED:20260128T055259Z
LAST-MODIFIED:20260128T062619Z
UID:8574-1769680800-1769684400@tcaofwa.org
SUMMARY:Pathways to SUD Treatment & Recovery
DESCRIPTION:Brought to you by SAMHSA: \nBerlina-Wallace Berube\, MACP\, MEd\, LCPC\, NCC\, will share information on multiple treatment protocols and recovery supports—all with the goal of helping people find the most appropriate means to attaining and retaining recovery. That will be immediately followed by a fireside chat between Angela Caldwell\, CSC-AD\, MS\, and David Awadalla\, MSW\, BSHP\, SAMHSA experts working in the Center for Substance Abuse Treatment and the Office of Recovery\, respectively. The duo will discuss the evolution of the concept of recovery\, as well as how centering individuals who have SUD during the treatment process can make a world of difference in their recovery efforts’ success. \nRegister here: Webinar Registration – Zoom \nVisit the 2026 SUD Treatment Month toolkit to find social media content and other materials. “Treatment works! Find the path that works for you.”
URL:https://tcaofwa.org/event/pathways-to-sud-treatment-recovery/
LOCATION:Online
CATEGORIES:SUD
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260128T090000
DTEND;TZID=America/Los_Angeles:20260128T100000
DTSTAMP:20260515T105452
CREATED:20260128T054934Z
LAST-MODIFIED:20260128T062702Z
UID:8572-1769590800-1769594400@tcaofwa.org
SUMMARY:SUD 101 Webinar
DESCRIPTION:Brought to you by SAMHSA: \n“Treatment works! Find the path that works for you\,” has been the theme for this year’s annual\, national SUD Treatment Month. Karran Phillips\, M.D.\, MSc\, the acting director of SAMHSA’s Center for Substance Abuse Treatment\, will present on SUD treatment options and on the work SAMHSA is doing to facilitate greater access to treatment and to more fully equip medical professionals in position to provide that treatment. \nClick here to register: Webinar Registration – Zoom \nVisit the 2026 SUD Treatment Month toolkit to find social media content and other materials.
URL:https://tcaofwa.org/event/sud-101-webinar/
LOCATION:Online
CATEGORIES:SUD
END:VEVENT
END:VCALENDAR